Hmg Coa Reductase Inhibitors



Indications and Reactions:

Role Indications Reactions
Secondary
Drug Use For Unknown Indication 33.3%
Blood Cholesterol Increased 12.5%
Hypercholesterolaemia 8.3%
Hypertension 8.3%
Peritoneal Dialysis 8.3%
Smoking Cessation Therapy 8.3%
Angina Pectoris 4.2%
Breast Cancer 4.2%
Bronchitis 4.2%
Haemorrhage 4.2%
Percutaneous Coronary Intervention 4.2%
Myocardial Infarction 16.7%
Blood Creatine Phosphokinase Increased 8.3%
Chest Pain 8.3%
Gamma-glutamyltransferase Increased 8.3%
Liver Function Test Abnormal 8.3%
Myopathy 8.3%
Pain In Extremity 8.3%
Rhabdomyolysis 8.3%
Thrombocytopenia 8.3%
Unevaluable Event 8.3%
Vomiting 8.3%
Concomitant
Type 2 Diabetes Mellitus 24.0%
Hypertension 20.2%
Product Used For Unknown Indication 15.4%
Diabetes Mellitus 9.8%
Atrial Fibrillation 4.4%
Drug Use For Unknown Indication 4.3%
Hyperlipidaemia 4.0%
Coronary Artery Disease 3.2%
Cardiac Failure 2.6%
Depression 2.0%
Prostate Cancer 1.6%
Cerebral Infarction 1.4%
Infected Skin Ulcer 1.1%
Renal Failure 1.0%
Arthritis Bacterial 0.9%
Blood Cholesterol Increased 0.9%
Cardiomyopathy 0.9%
Device Therapy 0.9%
Transient Ischaemic Attack 0.9%
Angina Pectoris 0.7%
Cardiac Failure Congestive 9.9%
Cerebral Infarction 7.7%
Acute Myocardial Infarction 6.6%
Fatigue 6.6%
Neoplasm Malignant 6.6%
Anaemia 5.5%
Cardiac Failure 5.5%
Hypoglycaemia 5.5%
Sudden Death 5.5%
Cerebral Haemorrhage 4.4%
Melaena 4.4%
Myocardial Infarction 4.4%
Transient Ischaemic Attack 4.4%
Angina Pectoris 3.3%
Cataract 3.3%
Chest Discomfort 3.3%
Constipation 3.3%
Dyspnoea 3.3%
Fall 3.3%
Haematuria 3.3%
Interacting
Blood Pressure 33.3%
Type 2 Diabetes Mellitus 33.3%
Chronic Myeloid Leukaemia 16.7%
Dyslipidaemia 16.7%
Suicidal Ideation 50.0%
Restlessness 25.0%
Rhabdomyolysis 25.0%